- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03071146
Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System (REALITY III)
August 20, 2018 updated by: C. R. Bard
A Prospective Study of the Performance of the Bard LifeStent 5F Vascular Stent System
The medical device being examined in this study is the Bard® LifeStent® 5F Vascular Stent System.
It is intended for use in patients who suffer from peripheral artery disease (PAD).
PAD is generally associated with blocked arteries of the legs.
The superficial femoral artery (SFA) and popliteal artery are common locations for this problem to develop.
The patient may experience pain or discomfort in the leg that occurs when walking or have other complications associated with wound healing.
The purpose of this study is to collect information to assess the deliverability, clinical utility, safety and effectiveness of the Bard® LifeStent® 5F Vascular Stent System.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gutleutstr. 1-14
-
Bruchsal, Gutleutstr. 1-14, Germany, 76646
- Fuerst-Stirum-Klinik Bruchsal
-
-
Heinz-Galinski-Str. 1
-
Berlin, Heinz-Galinski-Str. 1, Germany, 13347
- Gemeinschaftspraxis fuer Radiologie
-
-
Strassburger Allee 4
-
Kaiserslautern, Strassburger Allee 4, Germany, 67657
- Praxis fuer Interventionelle Angiologie
-
-
Suedring 15
-
Bad Krozingen, Suedring 15, Germany, 79189
- Universitaets-Herzzentrum Freiburg, Klinik fuer Kardiologie und Angiologie II
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This study will be conducted among patients who are candidates for PTA and stenting with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery).
Description
Inclusion Criteria:
- The subject or legal representative has been informed of the nature of the evaluation, agrees to its provisions, and has signed the informed consent form (ICF).
- Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
- The subject is ≥ 21 years of age.
- The subject has lifestyle-limiting claudication to mild tissue loss defined as: Rutherford Category 2-5 (moderate claudication to minor tissue loss).
- The target lesion(s) has angiographic evidence of a hemodynamically relevant stenosis or restenosis ≥50% or occlusion of the SFA and/or popliteal artery (by visual estimate) and is amenable to PTA and stenting.
- The target vessel reference diameter will be (by visual estimate) appropriate for treatment with available stent diameters of 5.0, 6.0 and 7.0 mm.
- A total of two stents may be used to treat a target lesion. Overlapping is allowed.
- There is angiographic evidence of at least one vessel runoff to the foot (at the level of the malleolus).
Exclusion Criteria:
- The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study follow-up procedure and visits.
- The subject has claudication or critical limb ischemia described as Rutherford Category 0 (asymptomatic), 1 (mild claudication), or 6 (major tissue loss).
- The subject has a known contraindication (including allergic reaction) or sensitivity to nickel, titanium or tantalum.
- The subject has a known allergy of hypersensitivity to contrast media which cannot be adequately pre-medicated.
- The subject has a known uncontrolled blood coagulation/bleeding disorder.
- The subject has concomitant renal failure with a creatinine of >2.5 mg/dL.
- The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study procedure.
- The subject is receiving dialysis or immunosuppressive therapy.
- The subject is diagnosed with septicemia at the time of the study procedure.
- The subject is participating in an investigational drug or another investigational device study.
- The subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be noncompliant with the protocol, confound the data interpretation, or is associated with limited life expectancy not sufficient to complete all study procedures.
- The subject has extensive peripheral vascular disease, which, in the opinion of the investigator, precludes safe insertion of an introducer sheath.
- The target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion.
- The subject has angiographic evidence of poor inflow, which would be deemed inadequate to support a vascular bypass graft.
- The subject has severe calcification of the target lesion, which prevents inflation of a PTA balloon (pre-dilatation of the target lesion is required).
- The subject has angiographic evidence of large acute thrombus at the target lesion.
- Subjects with a stent previously implanted into the target lesion. A target vessel with a previously placed stent is permitted as long as the subject device(s) will not come into contact with the previously placed stent during treatment of the target lesion.
- Lesion requiring the use of more than two stents.
- Bilateral disease in the native SFA and/or popliteal artery where both limbs meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30 days. Note: One limb may be enrolled in the study, but only if the second limb is planned to be treated after the 30 day follow-up telephone screening has taken place. The limb that may be enrolled has to be the limb with the more severe lesion and the reasons for treating this specific limb will need to be stated in the case report form (CRF).
- The subject had a prior vascular intervention within 30 days before, or has an intervention planned for within 30 days after the index procedure. Note: Additional non-target lesions may be treated during the index procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Bard® LifeStent® 5F Vascular Stent System
Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
|
The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from occurrence of death
Time Frame: 30 days post-index procedure
|
30 days post-index procedure
|
|
Freedom from occurrence of amputation
Time Frame: 30 days post-index procedure
|
30 days post-index procedure
|
|
Freedom from TLR (Target Lesion Revascularization)
Time Frame: 30 days post-index procedure
|
TLR is defined as a revascularization procedure (e.g.
PTA, cryoplasty, etc.) of the target lesion.
|
30 days post-index procedure
|
Freedom from TVR (Target Vessel Revascularization)
Time Frame: 30 days post-index procedure
|
TVR is defined as a revascularization procedure (e.g.
PTA, stenting, surgical bypass, etc.) of the target vessel outside the target lesion.
|
30 days post-index procedure
|
Technical success
Time Frame: At the time of index procedure (usually within 10 minutes)
|
Technical success is defined as successful deployment and placement accuracy based upon a rating scale completed by the investigators.
bookend sizes will be evaluated for clinical utility of size range.
|
At the time of index procedure (usually within 10 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from TLR (Target Lesion Revascularization)
Time Frame: Up to 12 months post-index procedure
|
TLR is defined as a revascularization procedure (e.g.
PTA, cryoplasty, etc.) of the target lesion.
|
Up to 12 months post-index procedure
|
Freedom from TVR (Target Vessel Revascularization)
Time Frame: Up to 12 months post-index procedure
|
TVR is defined as a revascularization procedure (e.g.
PTA, stenting, surgical bypass, etc.) of the target vessel outside the target lesion.
|
Up to 12 months post-index procedure
|
Primary patency rates
Time Frame: Up to 12 months post-index procedure
|
Patency is defined as a reduction in luminal diameter (stenosis) of <=50% and of <=70% measured by Duplex ultrasound (DUS) (peak systolic velocity ratio or PSVR <= 2.4 and <=3.4).
Failure of primary patency is defined as a restenosis (reduction in luminal diameter of >50%) as measured by DUS (PSVR >2.4).
|
Up to 12 months post-index procedure
|
Freedom from death
Time Frame: 12 months post-index procedure
|
TLR is defined as a revascularization procedure (e.g.
PTA, cryoplasty, etc.) of the target lesion.
TVR is defined as a revascularization procedure (e.g.
PTA, stenting, surgical bypass, etc.) of the target vessel outside the target lesion.
|
12 months post-index procedure
|
Freedom from occurrence of stroke
Time Frame: 12 months post-index procedure
|
12 months post-index procedure
|
|
Freedom from occurrence of MI (myocardial infarction)
Time Frame: 12 months post-index procedure
|
12 months post-index procedure
|
|
Occurrence of emergent surgical revascularization of the target limb
Time Frame: 12 months post-index procedure
|
12 months post-index procedure
|
|
Occurrence of significant distal embolization in target limb
Time Frame: 12 months post-index procedure
|
12 months post-index procedure
|
|
Occurrence of target limb major amputation
Time Frame: 12 months post-index procedure
|
12 months post-index procedure
|
|
Occurrence of thrombosis of target vessel
Time Frame: 12 months post-index procedure.
|
12 months post-index procedure.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Thomas Zeller, MD, Universitaets-Herzzentrum Freiburg, Bad Krozingen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2017
Primary Completion (Actual)
May 4, 2017
Study Completion (Actual)
May 31, 2018
Study Registration Dates
First Submitted
February 21, 2017
First Submitted That Met QC Criteria
February 28, 2017
First Posted (Actual)
March 6, 2017
Study Record Updates
Last Update Posted (Actual)
August 21, 2018
Last Update Submitted That Met QC Criteria
August 20, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BPV-16-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Bard® LifeStent® 5F Vascular Stent System
-
C. R. BardCompleted
-
C. R. BardCompletedPeripheral Artery DiseaseGermany
-
C. R. BardTerminatedSuperficial Femoral Artery StenosisUnited States
-
C. R. BardMedicon, Inc.Completed
-
W.L.Gore & AssociatesCompleted
-
Cook Group IncorporatedCompleted
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Rennes University HospitalTerminatedStenosis of Arteriovenous Dialysis FistulaFrance
-
Abbott Medical DevicesBaim Institute for Clinical ResearchWithdrawnWith de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
-
C. R. BardCompletedPeripheral Artery DiseaseGermany